Dry Age-Related Macular Degeneration (Dry AMD) Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Key Companies - Aevitas, nflammX, Alexion, Belite Bio, Katairo, Apellis, Galimedix, Aviceda

The Dry Age-Related Macular Degeneration (Dry AMD) Market size in the seven major markets was estimated to be USD 1,377 million in 2021. As per DelveInsight, the Dry Age-Related Macular Degeneration Market is anticipated to evolve immensely in the coming years owing to the rise in the number of prevalent cases of Dry AMD in the 7MM, the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and the expected launch of emerging therapies during the forecast period.

DelveInsight's "Dry Age-Related Macular Degeneration (Dry-AMD) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dry Age-Related Macular Degeneration Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Dry Age-Related Macular Degeneration therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dry Age-Related Macular Degeneration treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Dry Age-Related Macular Degeneration (Dry-AMD): An Overview
According to the American Macular Degeneration Foundation, dry age-related macular degeneration (Dry-AMD) is a type of macular degeneration in which the deterioration of the retina is associated with the formation of small yellow deposits, known as drusen, under the macula. This phenomenon leads to a thinning and drying out of the macula, causing the macula to lose its function. The amount of central vision loss is directly related to the location and amount of retinal thinning caused by the drusen.

Out of two types of AMD (wet and dry), Dry-AMD is quite common. About 80% (8 out of 10) of people who have AMD have the dry form. According to Prevent Blindness, dry AMD is caused by the appearance of small yellow deposits called drusen, which form under the retina. These are accumulated waste products of the retina, which can grow in size. This can cause the retinal cells in the macula that process light to die, causing vision to become blurred. This form of the disease usually worsens slowly.

Dry Age-Related Macular Degeneration (Dry-AMD) Market Key Facts
• As per Prevent Blindness, age-related macular degeneration affects an estimated 1.8 million Americans aged 40 years and older and an additional 7.3 million with large drusen are at substantial risk of developing AMD.
• The total diagnosed cases of dry AMD in the US by age distribution were 2,175,000+, 3,380,000+, 3,495,000+, and 2,614,000+ cases for the age group 50-59 years, 60-69 years, 70-79 years, and ≥ 80 years in 2021.
• In the EU5 countries, the total diagnosed cases of dry AMD by stages were 14,774,000+, and 1,136,000+ cases for early and intermediate dry AMD and advanced (geographic atrophy associated with dry AMD) in 2021. Germany accounted for the highest number of cases of moderate-to-severe whereas Spain accounted for the least number of cases of moderate-to-severe in 2021.
• As per a study by Owen et al.(2012), for the UK, it was found that the overall prevalence of late AMD was 2.4% equivalent to 513 000 cases. Prevalence were 4.8% aged ≥65 years, 12.2% aged ≥80 years.
• Key players like Apellis Pharmaceuticals (Pegcetacoplan), Iveric bio (Zimura), Genentech/ Roche (RO7171009; RG6147), Ionis Pharmaceuticals/ Roche (IONIS-FB-LRx), Allegro Ophthalmics (Luminate), NGM Biopharmaceuticals (NGM621), Stealth BioTherapeutics (Elamipretide), Regenerative Patch Technologies (CPCB-RPE1), CellCure Neurosciences/ Lineage Cell Therapeutics/ Roche (OpRegen), Gyroscope Therapeutics/ Novartis (GT005), Regenerative Patch Technologies (CPCB-RPE1), Luxa Biotechnology (RPESC-RPE-4W) and others. and others are involved in developing treatments for dry AMD.

Discover How Dry Age-Related Macular Degeneration Market will Grow by 2032:
https://www.delveinsight.com/report-store/dry-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Dry Age-Related Macular Degeneration (Dry-AMD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dry Age-Related Macular Degeneration therapies in the market. It also provides a detailed assessment of the Dry Age-Related Macular Degeneration market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Dry Age-Related Macular Degeneration drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Dry Age-Related Macular Degeneration (Dry-AMD) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Dry Age-Related Macular Degeneration patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Dry Age-Related Macular Degeneration Epidemiology Segmented as -
• Total Prevalent cases of Age-related Macular Degeneration in the 7MM [2019-2032]
• Type-specific (Dry-AMD, Wet-AMD) Prevalence of Age-related Macular Degeneration in the 7MM [2019-2032]
• Stage-specific Prevalence of Dry Age-related Macular Degeneration in the 7MM [2019-2032]
• Age-specific Prevalence of Dry Age-related Macular Degeneration in the 7MM [2019-2032]
• Geographic Atrophy (GA) Cases by Visual Impairment in the 7MM [2019-2032]

Get Key Insights Into the Evolving Dry Age-Related Macular Degeneration Epidemiology Trends:
https://www.delveinsight.com/report-store/dry-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Dry Age-Related Macular Degeneration (Dry-AMD) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dry Age-Related Macular Degeneration market or expected to be launched during the study period. The analysis covers the market share by Dry Age-Related Macular Degeneration drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Dry Age-Related Macular Degeneration Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/dry-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Dry Age-Related Macular Degeneration (Dry-AMD) Therapeutics Assessment
Several major pharma companies developing therapies for Dry Age-related Macular Degeneration. Currently, Alkeus Pharmaceuticals is leading the therapeutics market with its Dry Age-related Macular Degeneration drug candidates in the most advanced stage of clinical development.

Dry Age-Related Macular Degeneration (Dry-AMD) Companies Active in the Therapeutic Market Include:
• Molecular Partners
• Stealth BioTherapeutics
• Regenerative Patch Technologies
• Aevitas Therapeutics
• NGM Biopharmaceuticals
• InflammX Therapeutics
• Lineage Cell Therapeutics
• Alexion AstraZeneca Rare Disease
• Belite Bio
• Katairo
• Cognition Therapeutics
• Apellis Pharmaceuticals
• Galimedix Therapeutics
• Amarna Therapeutics
• 4D Molecular Therapeutics
• Aviceda Therapeutics
• Isarna Therapeutics
And Many Others

Dry Age-Related Macular Degeneration (Dry-AMD) Therapies Covered in the Report Include:
• ALK-001: Alkeus Pharmaceuticals
• Elamipretide: Stealth BioTherapeutics
• CPCB-RPE1: Regenerative Patch Technologies
• AAV.sFH: Aevitas Therapeutics

Learn More About the Emerging Therapies & Key Companies in the Dry Age-Related Macular Degeneration Therapeutics Market:
https://www.delveinsight.com/sample-request/dry-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Dry Age-Related Macular Degeneration Competitive Intelligence Analysis
4. Dry Age-Related Macular Degeneration Market Overview at a Glance
5. Dry Age-Related Macular Degeneration Background and Overview
6. Dry Age-Related Macular Degeneration Patient Journey
7. Dry Age-Related Macular Degeneration Epidemiology and Patient Population
8. Dry Age-Related Macular Degeneration Treatment Algorithm, Current Treatment, and Medical Practices
9. Dry Age-Related Macular Degeneration Unmet Needs
10. Key Endpoints of Dry Age-Related Macular Degeneration Treatment
11. Dry Age-Related Macular Degeneration Marketed Products
12. Dry Age-Related Macular Degeneration Emerging Therapies
13. Dry Age-Related Macular Degeneration Seven Major Market Analysis
14. Attribute Analysis
15. Dry Age-Related Macular Degeneration Market Outlook (7 major markets)
16. Dry Age-Related Macular Degeneration Access and Reimbursement Overview
17. KOL Views on the Dry Age-Related Macular Degeneration Market.
18. Dry Age-Related Macular Degeneration Market Drivers
19. Dry Age-Related Macular Degeneration Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/dry-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Other Trending Healthcare Reports by DelveInsight
• Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market

• Ocular Melanoma Market
https://www.delveinsight.com/report-store/ocular-melanoma-market

• Orthostatic Hypotension Market
https://www.delveinsight.com/report-store/orthostatic-hypotension-market

• Osteochondrodysplasia Market
https://www.delveinsight.com/report-store/osteochondrodysplasia-market

• Pars Plantis Market
https://www.delveinsight.com/report-store/pars-plantis-market

• Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market

• Respiratory Distress Syndrome Market
https://www.delveinsight.com/report-store/respiratory-distress-syndrome-market

• Tendonitis Market
https://www.delveinsight.com/report-store/tendonitis-market

• Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market

• Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

• Traveler's Diarrhea Market
https://www.delveinsight.com/report-store/travelers-diarrhea-market

• Usher Syndrome Market
https://www.delveinsight.com/report-store/usher-syndrome-market

• Varicose Veins Market
https://www.delveinsight.com/report-store/varicose-veins-market

• Vulvodynia Market
https://www.delveinsight.com/report-store/vulvodynia-market

• Wide Neck Bifurcation Intracranial Aneurysms Market
https://www.delveinsight.com/report-store/wide-neck-bifurcation-intracranial-aneurysms-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.